Our Science

A single mRNA molecule, as the short-living copy of a single gene, can generate thousands of therapeutic protein molecules at the site of action – combining both power and precision.  
Our focus is on targets such as cytokines, transcription factors, and bioactive peptides. These typicaly have shorter mRNA sequences, which offer distinct advantages: compatibility with co-formulation, streamlined chemical synthesis, and enhanced delivery efficiency.  

Efficient delivery systems are essential to unlock the full potential of mRNA therapeutics. Lipid nanoparticles (LNPs) have become the gold standard for delivery. LNPs shield mRNA from enzymatic degradation, facilitate cellular uptake via endocytosis, and promote endosomal escape to ensure translation in the cytoplasm. Yet, systemic administration often leads to non-specific uptake by organs like the liver and spleen. At Mercurna, we developed a formulation with reduced aspecific uptake and make use of a modular architecture that allows integration of targeting ligands. 

Targeted delivery is critical for directing therapies to the intended cell types and tissues. Precise delivery is critical to ensure therapies reach the intended cells and tissues, increasing therapeutic efficiency and reducing side effects. 
Our lead formulation features a proprietary kidney-targeting that binds with high affinity to a receptor located in the glomerulus. By decorating our LNPs with this peptide, we can enable delivery to kidney cells, thereby minimizing off-target effects commonly associated with current treatments.